Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Melanoma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Melanoma
    TopAbstracts in Melanoma 10/21/2009 - (DGNews)
    TopAbstracts in Melanoma 09/23/2009 - (DGNews)
    Study Reveals New Genetic Mutations Involved in Melanoma - (DGNews)
    TopAbstracts in Melanoma 08/26/2009 - (DGNews)
    Budesonide Fails as Diarrhoea Prophylactic in Melanoma Patients Receiving Ipilimumab - (DGNews)

    News archive

     Recent webcasts/CME - Melanoma
    • Moving Beyond Standard Therapy in Malignant Melanoma: Novel Agents and Combinations
    • Adjuvant Interferon Therapy Prolongs Relapse-Free Interval and Survival in Melanoma
    • Rational Vaccine Strategies May Better Harness the Immune System for Anticancer Response in Melanoma
    • Response May Not Be an Appropriate Endpoint for Evaluating Benefit From CTLA-4 Antagonists in Melanoma
    • Emerging Strategies for the Treatment of Metastatic Melanoma: The Role of Monoclonal Antibodies in Targeted Immunotherapy

      Webcasts/CME archive

       Recent cases - Melanoma
        Diffuse Anorectal Melanoma; Review of the Current Diagnostic and Treatment Aspects Based on a Case Report
        Malignant Melanoma Associated with a Blue Naevus: A Case Report
        Metastatic Malignant Melanoma of the Conjunctiva: A Case Report
        Delayed Malignant Melanoma Recurrence Simulating Primary Ovarian Cancer
        A 90-Year-Old Woman with an Asymptomatic Spot on Her Cheek

        Cases archive
          




        my personal edition > melanoma > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Melanoma Patients And Selective Sentinel Lymph Node Dissection

        A DGReview of :"Clinical Outcome of Stage I/II Melanoma Patients After Selective Sentinel Lymph Node Dissection: Long-Term Follow-Up Results"
        Journal of Clinical Oncology (JCO)

        03/20/2003
        By Anne MacLennan


        Triple-technique sentinel lymph node (SLN) dissection is reliable and accurate in melanoma patients, say researchers.

        The success rate is 99.5%, report investigators from VU University Medical Center, Amsterdam, the Netherlands.

        Although survival data appear promising in this study, the therapeutic effect of the procedure is still questionable, note Dr R J Vuylsteke and colleagues. However, as illustrated in this study, not all SLN-positive patients have a poor prognosis.

        There has been no final proof the SLN procedure influences disease outcome in melanoma patients although SLN status is part of the new American Joint Committee on Cancer staging system. These investigators examined accuracy of the procedure and clinical outcome in 209 patients after at least 60 months of follow up.

        The patients, who were seen between 1993 and 1996 and had stage I/II cutaneous melanoma, underwent selective SLN dissection by the triple technique. If the SLN contained metastatic disease, a completion lymphadenectomy was done.

        For survival analyses, the investigators used the Kaplan-Meier approach. Factors linked with survival were analysed via the Cox proportional hazards regression model. They found success rate was 99.5% after a median follow-up of 72 months. Forty (19%) of the patients had a positive SLN, whereas the false-negative rate was 9%.

        For the entire group, 5-year overall survival was 87%. It was 92 and 67%, respectively, for SLN-negative and SLN-positive patients.

        All patients with a positive SLN and a Breslow thickness of 1.00 mm or less survived, and those with a Breslow thickness less than 2.00 mm tended to have a better prognosis as compared with SLN-negative patients with a Breslow thickness greater than 2.00 mm.

        Independent prognostic factors for overall survival were found to be SLN status, Breslow thickness and lymphatic invasion, the study found.
        J Clin Oncol 2003 Mar 15;21:6:1057-65. "Clinical Outcome of Stage I/II Melanoma Patients After Selective Sentinel Lymph Node Dissection: Long-Term Follow-Up Results"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send